Precigen, Inc. (NASDAQ:PGEN) Receives $8.50 Average Target Price from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have received a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.

Several research firms recently weighed in on PGEN. Zacks Research lowered Precigen from a “hold” rating to a “strong sell” rating in a report on Thursday, January 22nd. HC Wainwright boosted their target price on shares of Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Wall Street Zen lowered Precigen from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Thursday, January 22nd.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 1,900,036 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total value of $7,942,150.48. Following the transaction, the director owned 341,189 shares of the company’s stock, valued at $1,426,170.02. This represents a 84.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 4,866,329 shares of company stock worth $20,233,899. Insiders own 47.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. NBC Securities Inc. acquired a new position in shares of Precigen in the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd bought a new position in Precigen during the 3rd quarter worth about $39,000. Russell Investments Group Ltd. bought a new position in Precigen during the 3rd quarter worth about $41,000. Mason Investment Advisory Services Inc. acquired a new stake in shares of Precigen in the 4th quarter valued at about $42,000. Finally, Asempa Wealth Advisors acquired a new position in shares of Precigen during the fourth quarter worth about $48,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Stock Down 3.5%

Shares of Precigen stock opened at $4.74 on Tuesday. The stock has a 50-day moving average price of $4.31 and a 200 day moving average price of $3.82. The company has a current ratio of 4.04, a quick ratio of 3.95 and a debt-to-equity ratio of 2.22. The company has a market cap of $1.68 billion, a P/E ratio of -3.41 and a beta of 1.07. Precigen has a 1 year low of $1.11 and a 1 year high of $5.22.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Precigen had a negative net margin of 3,912.92% and a positive return on equity of 1,066.10%. The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $0.67 million. As a group, analysts expect that Precigen will post -0.32 EPS for the current fiscal year.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.